Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
hey were educated about the 7- step hand-washing technique trainings
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Loperamide Hydrochloride Capsules USP, 2 mg had annual sales of US $34.7 million in the United States
Subscribe To Our Newsletter & Stay Updated
